All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q4 report for FRESENIUS KABI USA LLC on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

All filings by FEROX STRATEGIES · Everything FRESENIUS KABI USA LLC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Trade (domestic/foreign)

General issues related to trade.

Health Issues

General healthcare issues related to biosimilar industries.

Pharmacy

General patent issues related to biosimilar industries.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.